Literature DB >> 6391368

Ceftazidime as initial therapy for suspected bacterial infections in hospitalized pediatric patients.

M D Reed, C A O'Brien, S C Aronoff, J D Klinger, J L Blumer.   

Abstract

Ceftazidime, a new beta-lactam antibiotic, was used to treat 60 children with suspected bacterial infections occurring outside the central nervous system. The patients ranged in age from 0.1 to 21 years and received 30 mg of ceftazidime per kg up to a total single dose of 1 g administered every 8 h. Fifty-three pathogens were isolated from 43 children before the initiation of therapy. All children responded clinically, although one child failed bacteriologically and five children were considered colonized at the end of ceftazidime therapy. Adverse reactions associated with ceftazidime administration were primarily alterations in laboratory parameters and were clinically insignificant. Ceftazidime administered on an 8-h dosing regimen is effective monotherapy for the treatment of childhood infections.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6391368      PMCID: PMC176161          DOI: 10.1128/AAC.26.3.318

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  The combination of pivmecillinam and pivampicillin in the treatment of acute enteric fever.

Authors:  D Tanphaichitra; A Bussayanond; O Christensen
Journal:  J Antimicrob Chemother       Date:  1981-07       Impact factor: 5.790

2.  Cefotaxime in the treatment of severe paediatric infections.

Authors:  C J Papadatos; D A Kafetzis; J Kanarios
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

3.  Development of meningitis during therapy with cefamandole.

Authors:  S C Aronoff; W Thomford; J S Bertino; W T Speck
Journal:  Pediatrics       Date:  1981-05       Impact factor: 7.124

4.  Meningitis due to Haemophilus influenzae type b resistant to ampicillin and chloramphenicol.

Authors:  N Uchiyama; G R Greene; D B Kitts; L D Thrupp
Journal:  J Pediatr       Date:  1980-09       Impact factor: 4.406

5.  Inhibition of beta-lactamase in penicillinase producing gonococci by clavulanic acid.

Authors:  B Van Klingeren; L J Van Wijngaarden
Journal:  J Antimicrob Chemother       Date:  1981-07       Impact factor: 5.790

6.  Development of Haemophilus influenzae meningitis in patients treated with cefamandole.

Authors:  S A Chartrand; M I Marks; R Roberts; D P Jubelirer; D C Plunket
Journal:  J Pediatr       Date:  1981-06       Impact factor: 4.406

7.  Pneumococci relatively resistant to penicillin: a prevalence survey in children.

Authors:  K C Anderson; M J Maurer; A S Dajani
Journal:  J Pediatr       Date:  1980-12       Impact factor: 4.406

8.  Treatment of severe neonatal infections with cefotaxime. Efficacy and pharmacokinetics.

Authors:  D A Kafetzis; D C Brater; A N Kapiki; C V Papas; H Dellagrammaticas; C J Papadatos
Journal:  J Pediatr       Date:  1982-03       Impact factor: 4.406

9.  Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

10.  GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.

Authors:  C H O'Callaghan; P Acred; P B Harper; D M Ryan; S M Kirby; S M Harding
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

View more
  5 in total

1.  Urinary alanine-aminopeptidase (AAP) excretion in patients with urinary tract infection treated with ceftazidime (CAZ) or cefotaxime (CTX) plus tobramycin (TOB).

Authors:  A Wiecek; F Kokot; W Grzeszczak
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

2.  Reversing the myths obstructing the determination of optimal age- and disease-based drug dosing in pediatrics.

Authors:  Michael D Reed
Journal:  J Pediatr Pharmacol Ther       Date:  2011-01

Review 3.  [Ceftazidime in the treatment of pediatric infections--a review].

Authors:  D Adam; R Tolxdorff-Neutzling
Journal:  Infection       Date:  1987       Impact factor: 3.553

4.  Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia.

Authors:  J C Engle; P W Lifland; C J Schleupner
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

5.  Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children.

Authors:  J L Blumer; M D Reed; G L Kearns; R F Jacobs; W M Gooch; R Yogev; K Willims; B J Ewing
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.